We have previously identified epithelial membrane protein 2 (EMP2) as a cell surface protein present in a number of tumors including glioblastoma but not in nonpathologic brain tissue.20,21 In in vitro and in vivo models of glioblastoma, EMP2 expression was associated with increased tumor size, vascularity, and VEGF-A expression.22 Furthermore, humanized monoclonal anti-EMP2 antibody leads to significant decreases in tumor load and angiogenesis.22 These experimental data suggest a potential antiangiogenic target in EMP2. This evidence concerns the gene VEGFA and glioblastoma.